HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A L’Oreal First: H1 Asia Pacific Sales Equal North America Take

This article was originally published in The Rose Sheet

Executive Summary

The France-based beauty giant is stepping up its advertising and promotional investments to target younger consumers in the region – particularly Chinese millennials increasingly receptive to luxury products – confident that growth rates won’t be leveling off any time soon.

You may also be interested in...



Revlon Highlights Flesh Beauty Launch, China Momentum In Q2 Report

The firm remains in brand- and digital-building mode, but it’s seeing marked progress while looking forward to planned H2 innovations and the impact of its recently introduced Flesh line of “inclusive” color cosmetics. Opportunity beckons in China, where Revlon’s second-quarter sales grew 46%.

L’Oreal’s Logocos Naturkosmetik Acquisition: A Shot In The Arm For Consumer Division?

L’Oreal aims to expand the German company’s Logona and Sante brands internationally, which could help accelerate growth in its Consumer Products business. Division head Alexis Perakis-Valat says the deal harnesses “one of today’s major beauty ascending trends.”

L’Oreal Grows Its Mass Offering, Social-Media Prowess With NYX Buy

L’Oreal’s acquisition of mass color brand NYX cosmetics could help improve the France-based firm’s performance in North America, where it has faltered of late.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel